Single-arm study to assess a potential effect of anti-IL-17 (Secukinumab) in the treatment of pyoderma gangrenosum

Technische Universität München, School of Medicine, represented by Dean0 个研究点目标入组 7 人开始时间: 2015年6月25日最近更新: 2020年3月18日

适应症

试验速览

暂无简介。

•Confirmed diagnosis of pyoderma gangrenosum, biopsy-proven, non-healing ulcer with primarily neutrophil infiltration, regardless of size and location, characterization of target lesion (size, PGA, duration, age 18-75 years of age, body weight = 40 kg and = 160 kg, signed informed consent from patient, the first two patients of the trial must have received one other treatment for pyoderma gangrenosum before being included.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 7
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•Permanent severe diseases, especially those affecting the immune system, pregnancy or breast feeding, history or presence of epilepsy, significant neurological disorders, cerebrovascular attacks or ischemia, myocardial infarction or cardiac arrhythmia which requires drug therapy, evidence of severe renal dysfunction or significant hepatic disease, history of irritable bowel disease, history of lymphoproliferative disorders, simultaneous participation in another clinical trial or participation in another clinical trial during the last 6 months.

发起方

Technische Universität München, School of Medicine, represented by Dean